Gain Therapeutics Receives FDA IND Approval to Initiate Phase 2 Clinical Trial for Rexaceract
GCase-Restoring Therapy for Parkinson's Disease
Gain Therapeutics' (GANX) rexaceract (GT-02287) is an orally administered, brain-penetrant small molecule that targets glucocerebrosidase (GCase). The commercial brand name is still in the pre-approval stage, and the international nonproprietary name, rexaceract, is used. It employs an allosteric modulation strategy to restore the function of misfolded GCase caused by GBA1 mutations and aging-related stress, thereby recovering lysosomal function and the alpha-synuclein processing pathway. Unlike levodopa, which only provides symptomatic relief, this therapy targets the underlying disease biology.
Target Engagement Confirmed in Phase 1b
The Phase 1b clinical trial (NCT06732180), conducted at seven sites in Australia, involved 21 patients with Parkinson's disease, with 19 completing the 90-day treatment period. Of these, 15 initially opted for a 9-month extension study, with the number of extension participants increasing to 16. In patients with high baseline cerebrospinal fluid (CSF) GluSph levels, the average reduction after 90 days was 81%, and the MDS-UPDRS scores remained stable across the entire cohort. However, as this is an exploratory biomarker result from a single-arm, small-scale trial, the disease-modifying effect needs to be validated in a randomized controlled trial.
FDA Approval Enables Phase 2 Transition
The U.S. FDA approved the Investigational New Drug (IND) application for rexaceract on June 29, 2026, allowing Gain Therapeutics to initiate a Phase 2 clinical trial in the United States. The company plans to initiate a Phase 2a trial in the third quarter of 2026, evaluating oral rexaceract in patients with early-stage Parkinson's disease in the United States, Australia, and Europe. The trial design includes patients with and without GBA1 mutations, which broadens the commercial potential compared to a GCase-targeting approach limited to the genetic subgroup.
The analysis of the Phase 1b extension study is scheduled for the fourth quarter of 2026, representing a key value inflection point alongside the initiation of the Phase 2 trial.
Market and Competitive Landscape
The global market for Parkinson's disease therapeutics is estimated at USD 7.75 billion in 2025, with levodopa-based therapies at the center of standard treatment. With no FDA-approved disease-modifying therapies, Roche (RHHBY) and Prothena (PRTA)'s anti-alpha-synuclein antibody, prasinezumab, has entered Phase 3 development (PARAISO). BIAL's paricertat, another GCase-targeting agent (BIA 28-6156), failed to meet its primary efficacy endpoint in a Phase 2b trial and was discontinued. This reduces the competitive space for rexaceract but also raises the bar for clinical validation of the GCase modulation mechanism.
The FDA's IND approval on June 29, 2026, represents a regulatory milestone for Gain Therapeutics (GANX), enabling the company to transition rexaceract from the Phase 1b biomarker signal to a multi-regional Phase 2a efficacy trial. The average 81% reduction in CSF GluSph in the high baseline GluSph group provides evidence of target engagement, but the data comes from a small, 21-patient single-arm study and does not confirm clinical disease modification. In the USD 7.75 billion Parkinson's disease market, where levodopa is the standard of care for symptomatic relief and there are no approved disease-modifying therapies, successful development of rexaceract holds significant commercial potential. From a competitive standpoint, Roche and Prothena's prasinezumab is ahead in Phase 3 development, while BIAL's GCase modulator, paricertat, was discontinued after failing in Phase 2b, making the consistency of MDS-UPDRS and biomarker data compared to the control arm in the Phase 2a trial a key value driver.